Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis

Publication date: Available online 21 October 2018Source: SteroidsAuthor(s): Laurie S. Conklin, Peter A. Merkel, Lauren M. Pachman, Hemang Parikh, Shefa Tawalbeh, Jesse M. Damsker, David D. Cuthbertson, Gabrielle A. Morgan, Paul A. Monach, Yetrib Hathout, Kanneboyina Nagaraju, John van den Anker, Carol A. McAlear, Eric P. HoffmanAbstractGlucocorticoids are standard of care for many chronic inflammatory conditions, including juvenile dermatomyositis (JDM) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We sought to define pharmacodynamic biomarkers of therapeutic efficacy and safety concerns of glucocorticoid treatment for these two disorders. Previous proteomic profiling of patients with Duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD) treated with glucocorticoids identified candidate biomarkers for efficacy and safety concerns of glucocorticoids. Serial serum samples from patients with AAV (n=30) and JDM (n=12) were obtained during active disease, and after treatment with glucocorticoids. For AAV, 8 of 11 biomarkers of the anti-inflammatory response to glucocorticoids were validated (P-value ≤0.05; CD23, macrophage-derived cytokine, interleukin-22 binding protein, matrix metalloproteinase-12, T lymphocyte surface antigen Ly9, fibrinogen gamma chain, angiopoietin-2 [all decreased], and protein C [increased]), as were 5 of 7 safety biomarkers (P-value ≤0.05; afamin, matrix metalloproteinase-3, insulin growth factor binding...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research